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Abstract
Introduction: Lipoprotein(a) is an independent risk factor for Ischaemic Heart Disease (IHD) in
the general population. There are conflicting reports in the extent of its association with IHD
among subjects with Type 2 diabetes mellitus (T2DM).
The aim was to determine the concentration of Lp(a) and its relationship with other lipids
parameters among Omani T2DM subjects with and without IHD. An over-night fasting blood
sample from 221 T2DM subjects (86 females and 135 males) and 156 non-diabetics (69 females and
87 males) aged 30–70 years (as control) was taken for lipid profile studies.
Results: Lp(a) was significantly lower (p = 0.012) among T2DM subjects 0.123(1.12) g/L compared
to non-diabetics 0.246 (1.18)g/L, irrespective of gender.
A significant correlation (Spearman correlation, P = 0.047) was revealed between Lp(a) and IHD
among Omani T2DM subjects. The proportions of T2DM subjects with IHD and an Lp(a) >0.3 g/L
was higher compared to T2DM without IHD irrespective of gender, for women 42% vs. 27% and
for men 17.5 vs. 8%, respectively.
A significant negative correlation existed between Lp(a) and triglycerides (r = 0.41, P = 0.002)
among T2DM subjects. In contrast, a significant positive correlation existed between Lp(a) and
LDL-chol among the non-diabetic subjects.
Women had significantly higher Lp(a) concentration compared to men ( 0.30 Vs. 0.16 g/L,
P < 0.0001) irrespective of the diabetic status.
Conclusion: Lp(a) is an independent risk factor for IHD among Omani T2DM subjects. Lp(a)
concentration was significantly lower and negatively correlated with triglycerides among Omani
diabetic compared to non-diabetic subjects.
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Introduction
Lipoprotein(a) is an LDL-like particle in which apo(a)- a
glycoprotein consisting of several repetitive kringle struc-
tures – is attached to apolipoprotein B by a disulphide
linkage [1]. Elevated concentration of Lp (a) has been
identified by a meta-analysis as a modest risk factor for
IHD in the general population [2,3]. There are contradic-
tory reports in the literature in terms of Lp(a) concentra-
tion among T2DM subjects, some studies reported lower
[3-7], others reporting higher, concentration compared to
non-diabetic subjects [8-10]. In terms of its
relationship with IHD, again controversy exists in the lit-
erature [11-13].
Variations in Lp(a) levels are mainly genetically deter-
mined [14]. Other factors like the diet, drugs, hormones
and glycemic control were also found to effect Lp(a) con-
centration [15,16]. Lp(a) has also been found to be influ-
enced by other lipid parameters an inverse relation was
revealed between Lp(a) and triglycerides and positive cor-
relation with total and LDL cholesterol among diabetic
subjects [17]. Therefore, this study was undertaken to
investigate the level of Lp(a) as well as its relationship
with other lipid parameters in a cohort of type 2 diabetic
subjects with and without IHD.
Methods
The institutional Ethics Committee approved the study
and all subjects gave their informed consent prior to par-
ticipating in this study. Subjects (221 diabetics, 86 women
and 135 men) aged 30–70 years attending Lipids and Dia-
betes clinics at Sultan Qaboos University Hospital were
selected for the study. 156 healthy (non-diabetics), age
matched, randomly selected volunteers from the thyroid
clinic (euthyroid subjects and under regular follow-up),
within the department and blood donors were selected as
control. Diagnosis of T2DM was based on clinical charac-
teristics, prior history of use of oral hypoglycaemic agents,
the presence of obesity, no history of ketosis, or strong
family history of diabetes. World Health Organization cri-
teria for diagnosis of T2DM either by an abnormal oral
glucose tolerance test (OGTT), two abnormal fasting
blood glucose (>7.0 mmol/L) or high HbA1c (>7%) were
fulfilled by all patients with type 2 diabetes. The propor-
tions of T2DM subjects on insulin, oral hypoglycaemic
agents or dietary control were 3%, 57% and 40%, respec-
tively. History of smoking, alcohol, exercise and prophy-
lactic drugs (e.g. β-blockers, aspirin, diuretics and
sulphonylureas) was collected. Blood pressure was meas-
ured using a digital sphygmomanometer with the patient
in the sitting position. Diagnosis of IHD was based on
having a myocardial infarction three months prior entry
to the study, stable angina pectoris with positive thallium
stress test, coronary angiogram and previous history of
Percutaneous Transluminal Coronary Angioplasty
(PTCA). Exclusion criteria were myocardial infarction
within three months prior to entry to the study, uncon-
trolled thyroid disease (hypo or hyperthyroidism), pro-
teinuria (positive urine protein dip-stick ×2), severe
hepatic impairment (chronic active liver disease or those
individuals with obstructive liver pattern), chronic kidney
disease (CKD) (creatinine level >114 μmol/L) and lipid
lowering agents.
Cholesterol (c), triglyceride (TG), and glucose measure-
ments were performed using timed endpoint enzymatic
methods on the Synchron CX system (Beckman, Rich-
mond, California). Within and between batch precisions
for cholesterol (4.3 mmol/L) were 3% and 4.5%, respec-
tively, for Tg (2.0 mmol/L) were 3% and 4%, respectively;
and for glucose (5.5 mmol/L) were 2% and 3%,
respectively.
HbA1c concentration was determined as a percentage of
total haemoglobin in whole blood on the Synchron CX
system (Beckman, Richmond, California) with within and
between batches precisions at a HbA1c concentration of
8.0% was 5% and 7.5%, respectively. High density choles-
terol (HDLc) was measured using a timed-endpoint direct
homogenous assay on the same system, within and
between batches precision (HDL 1.2 mmol/L) were 2.5%
and 3%, respectively. Apolipoprotein A-1 (apoA1), apoli-
poprotein B (apoB) and Lp(a) were determined using rate
nephelometric immunochemistry assay by IMMAGE sys-
tem (Beckman, Richmond, California). [18] The within
and between batches precision profile of Lp(a) at levels of
0.060 g/L, 0.40 g/l and 0.90 g/L were 3.2%, 2.7%, and
3.0%, and 3.5%, 3.1%, and 3.6%, respectively. Within
and between batches precision profile for apoB (1.2 g/L)
were 2.5% and 2.9%, respectively; for apoA-1 (1.05 g/L)
were 3.4% and 3.9%, respectively. Low density cholesterol
(LDLc) was calculated using the Friedwald formula and
was not calculated when Tg level was >4.0 mmol/L.
Statistical analysis
Data was analyzed with the Statistical Package for the
Social Sciences Software (SPSS version 10). [19] Descrip-
tive analysis including the estimation of mean values and
standard error of the mean (SEM) for continuous varia-
bles were calculated Skewed parameters were logarithmi-
cally transformed and a parametric test was used.
Correlations between the different lipid parameters and
Lp(a) were carried out using Spearman correlation. Anal-
ysis of variance (ANOVA) was used to determine differ-
ences in subject characteristics. P value (two-tailed) < 0.05
was considered as statistically significant. A non-paramet-
ric test (Mann-Whitney) test was used to compare the cor-
relation between lipid parameters and non-parametric
variable like diabetes and IHD. Binary regression analysis
was carried out to study the of lipid parameters on Lp(a)Lipids in Health and Disease 2007, 6:26 http://www.lipidworld.com/content/6/1/26
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after adjusting for other observational variables like age,
gender, BMI.
Results
Lp(a), Tg, and HDLc were positively skewed, therefore,
natural logarithms of the data were used in all parametric
significance testing.
T2DM subjects had significantly lower concentration of
Lp(a) (P = 0.012) and higher TG (P < 0.0001) concentra-
tion compared to non-diabetic subjects. Women had sig-
nificantly higher Lp (a) and lower HDLc (P < 0.0001)
concentration compared to men (Table 1).
A significant Spearman correlation was revealed between
Lp(a) and IHD among Omani T2DM subjects. The mean
Lp(a) concentration was found to be higher among T2DM
subjects with established IHD compared to T2DM with-
out IHD. However, this did not reach statistical signifi-
cance (P = 0.12) (Table 2). The proportions of T2DM
subjects with IHD and an Lp(a) >0.3 g/L was higher
compared to T2DM without IHD irrespective of gender,
for women 42% vs. 27% and for men 17.5 vs. 8%,
respectively.
Regression analysis adjusted for age, gender, BMI and
HBA1c, revealed a significant (P = 0.002) negative correla-
tion between Lp(a) and the triglycerides among T2DM
subjects. In contrast, a significant positive correlation
existed between Lp(a) and the apoB and LDLc (P = 0.001
and P = 0.02, respectively) among the non-diabetic sub-
jects only (Table 3).
Discussion and conclusion
This study revealed that Lp(a) concentration was lower
among Omani T2DM compared to non-diabetics subjects
irrespective to gender. In contrast women had significantly
higher Lp(a) concentration compared to men irrespective
to the diabetic state. Similar findings to ours were also
reported by Calmarza et al. and Gazzaruso et al., lower
Lp(a) concentration noticed among T2DM compared to
non-diabetics subjects [4,5]. In another study, Abdella et
al., reported higher Lp(a) concentration among Kuwaiti
T2DM women compared to men [20].
The present study revealed a significant negative correla-
tion between Lp(a) and serum triglycerides among Omani
T2DM subjects. This observation agrees with those
reported by, Hernandex et al., using a different method for
Lp(a) measurement [17]. In another study, lower concen-
trations of Lp(a) were reported in subjects with lipopro-
tein lipase deficiency [21], and it is tempting to speculate
that diabetic subjects have some degree of functional defi-
ciency of lipoprotein lipase that is implicated in the patho-
genesis of hypertriglyceridaemia [22]. The likely
explanation behind this inverse relationship is the fact
that apo(a) is present in triglyceride-rich particles (TRPs).
Apo(a)-containing TRPs, in parallel with chylomicron
remnants, would be rapidly taken up by the liver through
the remnant-receptor pathway. Thus, the lower levels of
Lp(a) in patients with elevated triglyceride could be the
result of the rapid catabolism of TRP apo(a) compared
with the slower apo(a) catabolism in the LDL density
range [17]. Supportive evidence to our findings was
reported by Ko et al. Iin their study, improving insulin
resistance in T2DM subjects by Rosiglitazone (Insulin sen-
sitizing agent) was associated with lowering of triglycer-
ides and increase in Lp(a) concentration [23].
The present study revealed that Lp(a) concentration is an
independent risk factor for IHD among Omani T2DM
subjects, irrespective of genders. Nevertheless, the actual
concentration of Lp(a) had not reached statistical signifi-
cance because of a number of limiting factors. Firstly; met-
abolic due to the accelerated catabolism of apo(a)-TRPs
particles. Secondly, gender influence, having subdivided
Table 1: Shows the demographic, clinical and metabolic characteristics of T2DM compared to non-diabetic subjects.
Non-diabetic subjects T2DM subjects
Females Male Both Females Males Both P-value 
(both)
Number 69 87 156 86 135 221
Age (years) 45(1.8) 43(1.7) 44(1.5) 47(0.9) 48(1.0) 47(0.8) 0.33
BMI (kg/m2) 33.4(2.6) 29.5(1.35) 30.7(1.26) 29.6(1) 30.5(0.8) 30.2(0.6) 0.71
Tg (mmol/L) 1.29 (1.12) 1.4(1.08) 1.36(1.06) 1.77(1.07) 1.86(1.06) 1.83(0.97) <0.0001
Tc (mmol/L) 5.9 (0.28) 5.6(0.18) 5.7(0.15) 5.9(0.18) 5.8(0.14) 5.9(0.11) 0.59
LDLc (mmol/L) 3.9(0.26) 3.4(0.17) 3.7(0.13) 3.8(0.16) 3.7(0.11) 3.7(0.09) 0.97
HDLc(mmol/L) 1.37(1) 1.1(1) 1.18(1.02) 1.20(0.9) 1.1(0.91) 1.14(0.9) 0.21
Lp(a) (g/L) 0.246 (0.18–
0.32)
0.15 (0.089–
0.179)
0.18 (0.122–
0.207)
0.165 (0.108–
0.223)
0.101 (0.078–
0.132)
0.123 (0.08–
0.146)
0.015
Data are n, means +/- SEMLipids in Health and Disease 2007, 6:26 http://www.lipidworld.com/content/6/1/26
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the studied groups by gender because of its confounding
influence, the number of subjects within each subgroup
became smaller and therefore, might have influenced the
power of the study. A number of studies had also failed to
show any significant association between Lp(a) and IHD
among T2DM subjects without any emphasis on the rea-
sons behind such findings [5,6,24]. On the contrary oth-
ers have reported significant association between Lp(a)
and IHD [9,25]. In summary. Lp(a) is an independent risk
factor for IHD among Omani diabetic subjects. This
present study highlights the complexity of lipoprotein
metabolism and the impact of the different lipids param-
eters on Lp(a) concentration. Therefore, interpretation of
Lp(a) should be cautiously exercised among diabetic
subjects.
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Table 2: Shows the demographic, clinical and metabolic characteristics of T2DM subjects with established IHD compared those 
without IHD.
T2DM without-IHD T2DM with IHD
Females Males Both Females Males Both P value Both
No 66 83 149 20 52 72
Age 44 (1.3) 41(1.2) 41.7 (1.14) 47 (2.8) 48 (1.4) 47.9 (1.3) 0.001
BMI 29.5(0.7) 32 (1.4) 31 (0.84 31.2 (0.95) 28 (0.60) 28.7 (0.55) 0.35
TG (mmol/L) 1.71(1.08)) 2.1(1.08) 1.96(1.06) 1.91(1.16) 1.53(1.08) 1.61(1.07) 0.06
Tc (mmol/L) 6.0 (0.21) 5.8 (0.16) 5.9 (0.14 5.9 (0.35) 5.5 (0.18) 5.7 (0.16) 0.25
LDLc(mmol/L) 3.91 (0.19) 3.63 (0.17) 3.8 (0.13) 3.68 (0.43) 3.71 (0.14) 3.7 (0.15) 0.65
HDL c (mmol/L) 1.22 (1.03) 1.13 (1.03) 1.17 (1.02) 1.26 (1.06) 1.13 (1.03) 1.19 (1.03) 0.51
Apo B (g/L) 1.28 (0.05) 1.20 (0.04) 1.23 (0.03) 1.33 (0.09) 1.24 (0.04) 1.26 (0.04) 0.53
ApoA1 (g/L) 1.2 (0.04) 1.13 (0.02) 1.16 (0.02) 1.2 (0.08) 1.18 (0.03) 1.21 (0.03) 0.24
Lp (a) g/L 0.32 (0.021–
1.14)
0.14 (0.09–0.42) 0.24 (0.021–
1.14)
0.38 (0.11–1.73) 0.200 (0.07–
0.78)
0.33 (0.090–
1.73)
0.12
Data are n, means +/- SEM., for Lp(a) median and anti
Table 3: Variables independently related to serum Lp(a) concentrations (log) in the Linear Regression Analysis.
BS E  o f  BTP  v a l u e
Subjects with Type 2 
diabetes
Log-TG - 0.550 0.187 - 2.936 0.002
apo B - 0.356 0.353 - 1.031 0.430
LDLc 0.098 0.080 1.231 0.221
Constant - 1.884 0.532 - 3.542 0.001
Non-diabetic subjects
Log-TG - 0.0949 0.235 - 0.404 0.688
apo B 1.359 0.477 3.500 0.001
LDLc 0.256 0.100 2.534 0.025
Constant - 2.964 0.636 - 6.618 <0.0001
B- slop, SE of B- standard error of the slop, T- T test. Variables also entered into the linear regression analysis but not included in the equation are, 
age, BMI, gender, HBA1c, HDL cholesterol.Lipids in Health and Disease 2007, 6:26 http://www.lipidworld.com/content/6/1/26
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